Valneva lifts EMA’s temporary restriction on use of chikungunya vaccine IXCHIQ in elderly
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Subscribe To Our Newsletter & Stay Updated